MIMEDX Announces Launch of AXIOFILL™
September 20, 2022 08:00 ET
|
MiMedx Group, Inc
Adds a Unique Collagen Matrix Particulate Derived from Human-Placental Tissue to the Growing $1B Surgical Recovery Market MARIETTA, Ga., Sept. 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc....
MIMEDX Announces Launch of AMNIOEFFECT™
September 19, 2022 07:00 ET
|
MiMedx Group, Inc
New Product Enables Company to Target Additional Surgical Procedures and Deepen Market Penetration in the Growing $1B Surgical Recovery Market MARIETTA, Ga., Sept. 19, 2022 (GLOBE NEWSWIRE) --...
MIMEDX EPIFIX® Receives Reimbursement Approval in Japan
September 12, 2022 16:30 ET
|
MiMedx Group, Inc
Provides Favorable Access to a New $500 Million Market for the Treatment of Refractory Diabetic and Venous Ulcers for EPIFIX – the First and Only Amniotic Tissue Product Approved for Use in Japan ...
MIMEDX Announces Leadership Transition
September 06, 2022 07:00 ET
|
MiMedx Group, Inc
K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG)...
Regenerative Engineering Society Establishes Award in Honor of MIMEDX Board Member, Dr. Cato T. Laurencin
August 26, 2022 09:00 ET
|
MiMedx Group, Inc
The Cato T. Laurencin Regenerative Engineering Founders’ Award Promotes Advancement of Scientific Leadership and Research in the Field of Regenerative Engineering MARIETTA, Ga., Aug. 26, 2022 ...
MIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 04, 2022 16:07 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management...
MIMEDX Announces Second Quarter 2022 Operating and Financial Results
August 02, 2022 16:05 ET
|
MiMedx Group, Inc
Second Quarter Net Sales of $66.9 Million Reflects Double-Digit Revenue Increase for the Fourth Consecutive Quarter in the Company's Continuing Portfolio of Products Achieves Strong Year-Over-Year...
MIMEDX Announces Formation of Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts
July 27, 2022 08:00 ET
|
MiMedx Group, Inc
Scientific Advisory Board Adds Multi-disciplinary Clinical and Scientific Expertise to Support Acceleration of the Company’s mdHACM Placental Biologics Pipeline MARIETTA, Ga., July 27, 2022 (GLOBE...
MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3
July 20, 2022 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., July 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report...
MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer
July 18, 2022 09:35 ET
|
MiMedx Group, Inc
Proven Biotech Executive Brings Versatile Leadership Experience MARIETTA, Ga., July 18, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational...